Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.

PloS one - 1 Jan 2011

Dayyeh Barham K Abu, Gupta Namrata, Sherman Kenneth E, de Bakker Paul I W, Chung Raymond T

Abstract excerpt

BACKGROUND: Genetic studies have demonstrated a strong association between single nucleotide polymorphisms (SNPs) at IL28B and response to treatment with peginterferon (PEG) and ribavirin (RBV) in HCV monoinfected persons. We sought to test these associations in a prospective PEG / weight based ribavirin (WBR) treatment trial (ACTG A5178) (National Institution of Health registration number NCT00078403) in persons...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coinfection
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Probability

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 22003405
DOI: 10.1371/journal.pone.0025753
PMCID: PMC3189209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.PMID 22003405Read ↗

Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.Semantic proximity Read ↗

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.Semantic proximity Read ↗

Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Semantic proximity Read ↗

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.Semantic proximity Read ↗

IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.Semantic proximity Read ↗

The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Host genomics and HCV treatment response.Semantic proximity Read ↗

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.Semantic proximity Read ↗

Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.Semantic proximity Read ↗

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.Semantic proximity Read ↗

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.Semantic proximity Read ↗

Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.